Arthur Allen | (TNS) KFF Health News When doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician Don Crosslin was an early beneficiary. Crosslin started the drug that July. His tumors shrank, then stabilized. But while the drug has helped keep him alive, its side effects have gradually narrowed the confines of his life, said Crosslin, 76, who lives in Ocala, Florida: “My appetite has been minimal.
Similar Stories to Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite Fda Challenge on Bing News
Tribune News Service, South Florida Sun-Sentinel
Fri, 05/10/2024 - 11:46am
Topics: arthur allen tns kff health don crosslin ocala florida july but i lumakras crosslin s richard pazdur new england journal medicine november elissa snook united states there s mark ratain chicago deciding dosage under project optimus lauren-jei mccarthy when julie gralow american society clinical oncology julie bullock donald harvey emory university american medical association sotorasib kras g12c california-san francisco kevan shokat figured they yale university grant gi the fda noted patients jill feldman kaiser permanente stephen shivinsky smaller doses and revenue fda mccarthy switching social security ratain a amgen s handling medicare medicaid services cms fda-approved aaron smith drug although j&j zytiga national comprehensive cancer network post-marketing emory s harvey it s kff health tribune content agency llc he a kff health kff health news i in crosslin fda project optimus amgen fda s the fda the ratain ratain university that s that harvey johnson company effects lung approval month spokesperson development label change patent study year costs showed conduct effort tumors shrank stomach process day tolerable mouth early accelerated brand roughly phase sores spend target longer effect quarter advanced professor docetaxel excess approach begun lot pay months
BING NEWS:
- Amgen adds BiTE to its cancer range as FDA clears Imdelltra
Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority review. Tarlatamab has been ...
05/16/2024 - 1:00 pm | View Link - FDA approves Amgen's treatment for most deadly form of lung cancer
The Food and Drug Administration on Thursday approved Amgen's treatment for patients with the most deadly form of lung cancer. The agency cleared the drug, called Imdelltra, as a second or later ...
05/16/2024 - 12:12 pm | View Link - Amgen: FDA Approves Imdelltra For Extensive-Stage Small Cell Lung Cancer Treatment
(RTTNews) - Amgen (AMGN) said that the U.S. Food and Drug Administration approved Imdelltra or tarlatamab-dlle for the treatment of adult patients with extensive-stage small cell lung cancer or ES ...
05/15/2024 - 1:00 pm | View Link - Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge
Crosslin's concern lies at the heart of an FDA effort ... lung cancer patients, sotorasib kept patients alive for about a month longer than docetaxel, the current, highly toxic standard of care.
05/7/2024 - 12:03 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more